Biofrontera Inc. (BFRI)
NASDAQ (CM) NASDAQ (CM) Primary 
XMUN 
Biofrontera Inc. (BFRI) Reports Q1 Loss, Beats Revenue Estimates
Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.47 per share a year ago.
Biofrontera Inc. (BFRI) Upgraded to Buy: Here's Why
Biofrontera Inc. (BFRI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Biofrontera Inc. (BFRI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Biofrontera Inc. (BFRI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Is Biofrontera Inc. (BFRI) Stock Outpacing Its Medical Peers This Year?
Here is how Biofrontera Inc. (BFRI) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
Biofrontera Inc. (BFRI) Q3 2025 Earnings Call Transcript
Biofrontera Inc. ( BFRI ) Q3 2025 Earnings Call November 13, 2025 10:00 AM EST Company Participants Hermann Lubbert - CEO, President & Chairman Eugene Leffler - Chief Financial Officer Conference Call Participants Ben Shamsian Bruce Jackson - The Benchmark Company, LLC, Research Division Presentation Operator Welcome to the Biofrontera Inc. Third Quarter 2025 Financial Results and Business Update Conference Call. [Operator Instructions].
Biofrontera Inc. (BFRI) Q2 2025 Earnings Conference Call Transcript
Biofrontera Inc. (NASDAQ:BFRI ) Q2 2025 Earnings Conference August 14, 2025 10:00 AM ET Company Participants Eugene Frederick Leffler - Chief Financial Officer Hermann Luebbert - CEO, President & Chairman Conference Call Participants Bruce David Jackson - The Benchmark Company, LLC, Research Division Jonathan Matthew Aschoff - ROTH Capital Partners, LLC, Research Division Andrew Barwicki - Unidentified Company Operator Good day, and welcome to the Biofrontera Inc. Second Quarter 2025 Financial Results and Business Update Conference Call. [Operator Instructions] Please note that today's event is being recorded.
Biofrontera Inc. (BFRI) Q1 2025 Earnings Call Transcript
Biofrontera Inc. (NASDAQ:BFRI ) Q1 2025 Earnings Conference Call May 16, 2025 10:00 AM ET Company Participants Andrew Barwicki - IR Representative Hermann Luebbert - CEO, Chairman, & Founder Fred Leffler - CFO Conference Call Participants Jonathan Aschoff - ROTH Capital Bruce Jackson - The Benchmark Company Operator Good day, and welcome to the Biofrontera's First Quarter 2025 Financial Results and Business Update Conference Call. All participants will be in listen-only mode.
Biofrontera Inc. (BFRI) Q4 2024 Earnings Call Transcript
Biofrontera Inc. (NASDAQ:BFRI ) Q4 2024 Earnings Conference Call March 21, 2025 10:00 AM ET Company Participants Andrew Barwicki - IR Representative Hermann Luebbert - CEO, Chairman, and Founder Fred Leffler - CFO Conference Call Participants Jonathan Aschoff - Roth Capital Bruce Jackson - The Benchmark Company Operator Good morning and welcome to the Biofrontera Fourth Quarter and Fiscal 2024 Financial Results and Business Update Conference Call. All participants will be in listen-only mode.
Biofrontera Inc. (BFRI) Q3 2024 Earnings Call Transcript
Biofrontera Inc. (NASDAQ:BFRI ) Q3 2024 Earnings Conference Call November 14, 2024 10:00 AM ET Company Participants Andrew Barwicki - Investor Relations Hermann Luebbert - Chief Executive Officer, Chairman and Founder Fred Leffler - Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH Capital Bruce Jackson - The Benchmark Company Operator Welcome to the Biofrontera Inc. Third Quarter 2024 Financial Results and Business Update Conference Call. [Operator Instructions] Please note this event is being recorded.
Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates
Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $4.64 per share a year ago.
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024
WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of PDT, announces it will report financial results for the three and nine months ended September 30, 2024 on Wednesday, November 13, 2024. The results will be released after the market close on Wednesday, Nov 13 and the company will host a conference call on Thursday, November 14 at 10:00am Eastern Time.
Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference
WOBURN, MA / ACCESSWIRE / September 25, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that management will present at the 3rd Annual ROTH Healthcare Opportunities Conference to be held at the Metropolitan Club in New York, NY. Date: October 9, 2024 Time of Presentation: 12:30 - 1:10 PM ET Format: Live Presentation 1x1 Meetings: Please contact your Roth representative About Biofrontera Inc. Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics.
